A 61-year-old man presented to the emergency department following an intentional overdose of 32 g of amisulpride (therapeutic dose: 50-1,200 mg/day). On arrival, he was unconscious (Glasgow Coma Score 3), had poor respiratory effort, hypotension (blood pressure 90/40 mm Hg) and hypothermia (temperature 32.4°C). An ECG demonstrated sinus rhythm, a heart rate of 90 bpm, with intermittent selfresolving ventricular tachycardia and a prolonged QTc interval (corrected QT time, calculated with Bazett' s formula, of 431 msec). Laboratory results included: Na + 141 mmol/L, Cl -102 mmol/L, K + 3.9 mmol/L and an ionised Ca 2+ of 1.17 mmol/L. Blood gases showed a lactic acidosis with a pH of 7.05, base deficit of -15 mmol/L and a lactate of 12 mmol/L. The initial plasma amisulpride level was found to be 50 mg/L. Immediate treatment consisted of intubation, mechanical ventilation and fluid resuscitation. The patient required vasopressor therapy with noradrenaline at a rate of 0.25 µg/kg/min. Despite receiving 5 litres of Hartmann' s solution and maintaining a central venous pressure of around 12 cm H 2 O, his noradrenaline requirements increased to 0.56 µg/kg/min.
Case history
A 61-year-old man presented to the emergency department following an intentional overdose of 32 g of amisulpride (therapeutic dose: 50-1,200 mg/day). On arrival, he was unconscious (Glasgow Coma Score 3), had poor respiratory effort, hypotension (blood pressure 90/40 mm Hg) and hypothermia (temperature 32. 4°C ). An ECG demonstrated sinus rhythm, a heart rate of 90 bpm, with intermittent selfresolving ventricular tachycardia and a prolonged QTc interval (corrected QT time, calculated with Bazett' s formula, of 431 msec). Laboratory results included: Na + 141 mmol/L, Cl -102 mmol/L, K + 3.9 mmol/L and an ionised Ca 2+ of 1.17 mmol/L. Blood gases showed a lactic acidosis with a pH of 7.05, base deficit of -15 mmol/L and a lactate of 12 mmol/L. The initial plasma amisulpride level was found to be 50 mg/L. Immediate treatment consisted of intubation, mechanical ventilation and fluid resuscitation. The patient required vasopressor therapy with noradrenaline at a rate of 0.25 µg/kg/min. Despite receiving 5 litres of Hartmann' s solution and maintaining a central venous pressure of around 12 cm H 2 O, his noradrenaline requirements increased to 0.56 µg/kg/min.
He was transferred to the intensive care unit (ICU) where haemodynamic assessment using the LiDCO Rapid © technique demonstrated a low cardiac output. Considered together with lactic acidosis, this suggested low global tissue perfusion. This was treated with dobutamine, while continuous veno-venous haemofiltration (CVVHF) and a simultaneous sodium bicarbonate infusion were initiated to reduce the immediate cardiovascular effects of the low pH. CVVHF was maintained almost continuously, at a dose of 35 mL/kg/h. Accusol 35 (Baxter International Inc.) was used as the buffer solution.
The plasma amisulpride level following haemofiltration was higher (59.5 mg/L) than the initial level, suggesting either a haemoconcentration effect or continued absorption.
The lactic acidosis resolved over the initial 12 hours, but significant cardiovascular instability was a continuing feature over the next few days. There were four recorded episodes of torsades de pointes, one example of which is shown in Figure 1 . One episode required a precordial thump, another direct current shock and others were self-resolving. These episodes resolved following further aggressive therapy, as suggested by TOXBASE, aimed at: • Maintenance of serum potassium, calcium, and magnesium levels at the high end of the normal range • Reduction of the QTc interval by increasing the heart rate above 100 bpm using an isoprenaline infusion. 1 After commencing the isoprenaline infusion, no further episodes of torsades de pointes occurred.
The maximum QTc of 725 msec (Figure 2 ) was recorded at 50 hours post-overdose. It remained elevated at 451 msec in spite of therapy until 190 hours post-overdose.
In view of the long-term ventilatory requirements, a tracheostomy was inserted on day eight. The patient was successfully decannulated on day 14 and made an uneventful and complete recovery.
Cardiovascular management of amisulpride overdose N Karunasekara, M Wilcox, N Tufft
A 61-year-old man took an amisulpride overdose of 32g. He developed severe cardiovascular instability with multiple episodes of torsades de pointes. Management was guided by current TOXBASE guidelines and the patient made a complete recovery. However, this case revealed certain questions surrounding the benefits, and associated risks, of recommended management. The literature links long QT syndrome with hypocalcaemia, hypomagnesaemia and hypokalaemia, underpinning the current TOXBASE guidelines, as discussed above. 1 Where extreme QTc prolongation (>575 msec) is present, TOXBASE suggests the use of a MgSO 4 infusion of 8 mmol over 10-15 minutes. 1 Figure 4 shows no correlation (regression value 0.1558) between plasma magnesium levels and QTc. The same infusion over 30-120 seconds is also first line suggested treatment for torsades de pointes.
The use of magnesium itself is not without risk, with hypermagnesaemia linked to muscle weakness, conduction abnormalities and interference with clotting. The overall benefit of repeated magnesium infusions is questioned. Figure 5 shows the relationship between ionised plasma calcium levels and the QTc interval. The regression value of 0.0369 suggests that even at the higher plasma ionised calcium levels, the QTc interval does not tend to decrease. In light of this data, we question the need for calcium replacement in long-QT cases. The side effects of hypercalcaemia (constipation, depression and confusion) should always be considered and its use questioned, in the same way as the use of magnesium.
In summary, our case highlights the importance of maintaining a heart rate of above 100 bpm to prevent deterioration of a long QT to torsades de pointes. We believe that a patient at risk should receive continuous cardiovascular monitoring until the QT interval has normalised. Vigilance for the possibility of deterioration into torsades should be high to prevent such a rhythm being inappropriately managed. Our data raises the question of whether calcium and magnesium infusions are indeed of any benefit in these cases. Further discussion regarding these cases, and issues raised, would prove helpful in determining the most appropriate management plan.
Discussion
Amisulpride (trade name Solian) is a benzamide derivative; it is an atypical antipsychotic used for the treatment of both the negative and positive symptoms of schizophrenia. It acts by selectively blocking both pre-synaptic and post-synaptic D 2 and D 3 receptors. 2 Amilsulpride' s significant cardiotoxicity in overdose has been reported previously. Isbister et al found that the cardiac side effects of amisulpride included abnormal QT interval (up to 750 msec), bradycardia, hypotension, tachycardia and torsades de pointes, occurring in 73%, 24%, 23%, 23%, and 7% of cases respectively. 3 Other cardiovascular findings include bifid T waves, broadcomplex tachycardias, and rate-dependent bundle branch block.
Therapeutic studies have found that the peak concentration after a 50 mg dose was 55.7 µg/L. 4 Using high-performance liquid chromatography, Isbister et al detected levels of 23.2 mg/L, 12.5 hours after a 32 g dose with a post-mortem level of 140 mg/L after an overdose of 16-24 g. Our patient' s peak serum amisulpride level reached 59.75 mg/L, greatly in excess of previously documented survivors. The decline in amisulpride level is shown in Figure 3 . Evidence that it took more than 217 hours for plasma levels to fall within therapeutic range.
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